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ABSTRACT
Chronic pressure overload (PO) due to arterial hypertension can lead to structural
changes within the heart including left ventricular hypertrophy (LVH) and eventually
diastolic heart failure (DHF). The initial diagnosis of PO and LVH is typically challenging
and costly, and thus, a new predictive diagnostic tool is desired. In a recent paper by Zile
et al., it was found, through the use of a simple multivariate logistic regression, that there
exists a multi-biomarker panel with predictive capabilities for the classification of patients
with LVH and DHF. In our new work, we furthered the investigation into the plasma
biomarker panel proposed by Zile et al. and have shown a proof-of-concept for predictive
capabilities of select biomarkers through the use of machine learning classification
strategies. An optimized ensemble boosting classification algorithm5 showed greater
promise for the diagnosis of LVH and DHF within this population of heart patients. In
select simulations, AdaBoost accurately categorized 79.2% of patients with LVH and
93.0% of patients with DHF with the inclusion of demographic, plasma biomarkers, and
select echocardiogram data, and 77.2% and 91.5%, respectively, of patients with only
select demographic and blood plasma panel data. Although these classification algorithms
show promise as a diagnostic tool, we believe that further investigation into the specific
biomechanical interactions involved in structural alterations of cardiac tissue through
collagen turnover is warranted. To better connect the remodeling-related biomarkers to
LVH and DHF prediction, we also constructed an ODE-based mechanistic model of type
I collagen and employed a genetic algorithm to determine kinetic parameters for the system
through DHF patient classification.
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CHAPTER ONE
INTRODUCTION
Although pressure induced left ventricular hypertrophy (LVH) leading to heart
failure is a large public health concern, there exists no simple method of early diagnosis.
Often times, patients undergo pressure overload (PO) for a prolonged amount of time due
to the lack of associated symptoms, and thus, left ventricular remodeling goes unnoticed,
leading to catastrophic results to the patient.1-4
Studies have shown that there are certain factors for patients that increase their risk
of developing LVH – such as older age, obesity, and hypertension – but alone are not
sufficient for clinically diagnosis.5 There has also been research into the application of
ECGs as a diagnostic tool of LVH; however, its low sensitivity towards a positive diagnosis
is undesirable.6,7 The current clinical diagnostic plan for LVH involves costly imaging
procedures such as echocardiograms, MRIs, or multislice CTs.5 These approaches all
require select equipment that is not always available to clinicians and require outside
experts in order to run and comprehend the data produced. Thus, it would be beneficial to
clinicians and patients to explore alternative diagnostic plans.
LVH acts as a risk factor to both abnormal diastolic function and chronic heart
failure. The remodeling of the heart tissue as a direct response may lead to abnormal left
ventricle filling, a stiffer left ventricle, and increased diastolic pressure, which could lead
to further abnormalities of the heart tissue.4 Prolonged periods of LVH may lead to diastolic
heart failure (DHF), which occurs with a preserved ejection fraction.8,9 The complete
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mechanistic pathway from hypertrophy to heart failure is unknown, and like LVH, its
diagnosis within patients requires costly and invasive approaches and testing.5
Pressure overload has been shown to produce changes in both the structural and
biochemical composition of heart tissue. A large component of the structural make-up of
cardiac tissue is fibrillar collagen, or type I collagen and type III collagen. Thus, it has been
shown that PO is correlated with an increase in extracellular matrix accumulation through
a change in both collagen production and degradation.10-14 The maturation to a collagen
fibril requires multiple processing steps, which leads to certain byproducts of these
reactions. Specifically, the cleavage of the N-terminal propeptide of procollagen type I and
procollagen type III (PINP and PIIINP) produces fragments that can be detected in a blood
sample, allowing for the quantification of collagen production. Alternatively, carboxylterminal telopeptide of collagen type I (CITP) is a product from the process of collagen
degradation, and thus can be used as a biomarker for the quantification of collagen
degradation.8
The group of interstitial proteases known as the matrix metalloproteinases (MMPs)
play a critical role in the process of collagen degradation.13 The MMP family consists of
23 uniquely functional proteases that can be grouped in terms of their substrate. The MMPs
focused herein are MMP-1 (collagenase), MMP-2 (gelatinase), MMP-3 (stromelysin),
MMP-7 (stromelysin), MMP-8 (collagenase), and MMP-9 (gelatinase). The group of
MMPs also has inhibitors, namely the tissue inhibitors of metalloproteinases (TIMPs),
which act upon both the mature proteases and the pro-proteases.14 In a previous
epidemiological study by our collaborator, Dr. Michael Zile, it was found that MMP-9 was
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a significant biomarker for the panel towards correct LVH diagnosis. TIMP1 plasma levels
were also increased in LVH patients.10 Likewise, it was found that MMP-2, MMP-7, and
TIMP4 levels were increased and MMP-8 levels were decreased in DHF patients when
compared to LVH patients.3 The increased levels of MMP-2 could indicate an alteration to
the tissue’s homeostasis where there is an increase in fibrillar collagen degradation.15 The
increased levels of MMP-7 could indicate an increase in the wound healing response due
to the remodeling of the ECM and its mimicking of an injury to the tissue.16 The increase
in TIMP-4 levels in patients with heart failure could be indicative of the suppression of
collagen degradation leading to an excessive build-up similar to fibrotic tissue.
Alternatively, the decreased levels of MMP-8 in DHF patients could indicate an alteration
to the neutrophils within the tissue and its compositional make-up.4
Recent studies into the application of machine learning techniques for the
classification of numerous pathologies have shown predictive capabilities of selective
biomarker panels.17,18 In this study, we look to expand on previous work by Zile et al. that
investigates the use of remodeling-related biomarkers for the classification of the
myocardial hypertrophic disease states, left ventricular hypertrophy and diastolic heart
failure.4 To improve the predictive power of these biomarkers for classification, we utilized
multiple advanced machine learning frameworks. Additionally, we set out to develop a
mechanistic model for type I collagen remodeling to be used in conjunction with the
aforementioned patient data. The patient-specific results from the mechanistic model were
then applied to the machine learning models in an attempt to improve the models’
predictive capabilities towards patient classification.
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CHAPTER TWO
METHODS
Processing of Patient Data
A patient database compiled by Zile et al. containing 480 patients was obtained. Of
the 480, there were 277 patients with no LVH diagnosis, 143 patients with an LVH
diagnosis but no DHF diagnosis, and 60 patients with both an LVH and DHF diagnosis.
The subjects of the database were chosen from health fairs, physician referral, and
echocardiographic studies.4 The patient array including patient demographics, biomarkers
derived from blood samples, and data from advanced imaging techniques were examined
and selectively extracted. The basic array of patient data included: sex, age, height, weight,
heart rate after a brisk, six minute hall walk, systolic blood pressure, diastolic blood
pressure, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9, TIMP-1, TIMP-2, TIMP3, TIMP-4, PINP, PIIINP, CITP, cardiotrophin (CT-1), N-terminal propeptide of brain
natriuretic peptide (NT-proBNP), soluble receptor for advanced glycation end products
(sRAGE), and osteopontin. This array excluded any patient data that necessitated any
advanced clinical imaging technique. The expanded array of patient data included all the
biomarkers included in the basic array, as well as mechanical biomarkers derived from
echocardiogram data: left ventricular internal diameter end diastole (LVIDd), left
ventricular internal diameter end systole (LVIDs), left ventricular end diastolic volume and
index (EDV and EDVi), left ventricular end systolic volume and index (ESV and ESVi),
stroke volume (SV), peak systolic stress (PSS), end systolic stress (ESS), and end diastolic
stress (EDS). The split of data into a limited array and an expanded array allowed for
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further analysis into the changes in predictive power brought about by the exclusion of any
data that require advanced imaging techniques.
The patients were split into their representative categories – total control patients,
patients with hypertension, patients with LVH, and patients with DHF. In order to maintain
consistency with the previous work conducted by Zile et al. the hypertensive patients were
grouped with the control patients. From this split, each patient was assigned a numerical
classifier that correlated to their clinical category. Within each patient group, the averages
of each marker were calculated. For patients with missing numerical biomarkers
originating from their initial clinical assessment, the average of the other patients within
the group was assigned to replace the missing value. The biochemical biomarkers were
converted to moles of solute per liter through each marker’s molecular mass in an effort to
improve biological relevancy for a mechanistic approach.14 For patients with missing
binary classifiers, such as biological sex, the average of their respective groups was taken,
and the closest binary classifier to the average was assigned to the missing values.
In order to maintain consistency across simulations, the data were normalized using
a common z-score approach which normalizes data with respect to the sample mean and
standard deviation. This approach was deemed important because the features on which
the models are trained are biomarkers with significantly different scales. Additionally, this
normalization ensures each feature can be better analyzed during feature selection. For
select algorithms, it has been proposed that the pre-standardization of data can provide
improved results.19
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Machine Learning Algorithms for Classification
The patient data to be used for classification were defined in two ways. In the first,
or limited array, the patient data were exclusively biochemical biomarkers from a blood
plasma panel, patient demographic information, and both diastolic and systolic blood
pressures. In the second, or expanded array, the patient data include all the information in
the previous array, as well as data gathered through more advanced clinical imaging
techniques, such as echocardiograms. The complete patient matrix was then imported into
the MATLAB Classification Learner within the Statistics and Machine Learning Toolbox,
R2019B, which was employed due to its ease of use for a variety of machine learning
classification approaches.
The seven chosen algorithms to be employed for patient classification were:
decision trees, discriminate analysis, logistic regression, naïve Bayes, support vector
machines, k-nearest neighbors, and ensemble algorithms. These supervised algorithms are
frequently used for binary classification problems, and they cover both probabilistic and
deterministic models. Decision trees utilize tree structures, where the root node
representing the feature space can be split through binary decisions and recursive
partitioning to lead to decisions about the class of a variable.20 Discriminate analysis
assumes that the conditional probabilities of each class follow a Gaussian distribution and
the model attempts to approximate these Gaussian parameters for class assignment.21 The
logistic regression approach looks to estimate parameters of a linear model that represents
the log-odds of particular class.22 A naïve Bayes classifier uses the naïve Bayes probability
model with a predetermined decision rule in order to create a classifier that minimizes the
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misclassification probability.23 A support vector machine model for classification seeks to
find a hyperplane within the subspace that can best separate data from each class.24 The knearest neighbors approach finds an object’s k-nearest neighbors through a distance metric,
and uses the neighbors’ classes for the object’s own classification.25 Ensemble approaches
to classification utilize multiple machine learning algorithms with the goal of having
improved performance over the individual components of the ensemble. Specifically, the
ensemble methods considered herein are bagging and boosting approaches. Bagging
methods generate new sample data sets from the training set and train models on each of
the sample sets. Each model is then combined through their classifications.26 Boosting
methods begin with a weak learning model that is iteratively added to stronger classifiers
through which the weak model can be re-weighted. A common method for boosting is
known as adaptive boosting (AdaBoosting), where a weak learning algorithm is called over
a selected series of rounds and the weights of distribution for each sample is maintained.
For each successive round of model addition, the weights of misclassified examples are
increased with the goal of increasing focus on the examples most frequently misclassified.
The final hypothesis of classification is then a majority vote of the previous weak
"

" % &!

hypotheses, each with their own parameter 𝛼, where 𝛼! = # 𝑙𝑛 %

&!

& , and 𝜖! represents

the error of the weak learner, ℎ! .27
The data were randomly split into training groups (80% of patients) and testing
groups (20% of patients) in which the models could be tested for performance. This split
describes the holdout method for the cross-validation of machine learning models. Due to
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the random splitting of the data into the training and testing sets, each classification
algorithm underwent three simulations in minimize the effect of skewed data splitting.
The training data were fed to the Classification Learner. Each of the approaches,
other than the simple logistic regression approach, was optimized using a Bayesian
hyperparameter optimization approach over 30 iterations. Bayesian optimization uses a
Gaussian process model of an objective function, a Bayesian update procedure for the
modification of the model, and an acquisition function that is maximized according to the
value of the expected improvement per second plus.28 The Gaussian process’s posterior
distribution allows for efficient use of experimental data as a means for subsequent
parameter selection. Accordingly, the optimizable hyperparameters for each machine
learning approach are described below. For the decision tree approach, the maximum
number of splits within the tree, as well as the criterion for splitting (Gini’s diversity index,
twoing rule, and maximum deviance reduction). For the discriminate analysis approach,
the discriminate type, including linear, diagonal linear, quadratic, and linear quadratic. For
the naïve Bayes approach, the distribution (Gaussian or Kernel), as well as the kernel type.
For the support vector machine approach, the kernel function (Gaussian, linear, quadratic,
and cubic), the box constraint level, and the kernel scale. For the k-nearest neighbor, the
number of neighbors, the distance metric (Euclidean, city block, Chebyshev, cubic,
Mahalanobis, cosine, correlation, Spearman, Hamming, and Jaccard), and the distance
weight (equal, inverse, squared inverse). For the ensemble approach, the method
(AdaBoost, RUSBoost, LogitBoost, GentleBoost, Bag), the maximum number of splits,
the number of learners, the learning rate, and the number of sampling predictors.29
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After training simulations, the accuracies of the testing groups were calculated
using the formula for accuracy of a binary classification model:
𝐴𝑐𝑐𝑢𝑟𝑎𝑐𝑦 =

'( ) '*
'( ) '* ) +( ) +*

.

Additionally, F1 scores and Matthews correlation coefficients30 were calculated by:
𝐹" =

𝑀𝐶𝐶 =

𝑇𝑃
𝑇𝑃 + :2 (𝐹𝑃 + 𝐹𝑁)
"

𝑇𝑃 × 𝑇𝑁 − 𝐹𝑃 × 𝐹𝑁
B(𝑇𝑃 + 𝐹𝑃)(𝑇𝑃 + 𝐹𝑁)(𝑇𝑁 + 𝐹𝑃)(𝑇𝑁 + 𝐹𝑁)

.

These additional statistical evaluations of the classifiers were needed because the
accuracy is not a perfect measure of a classifier’s ability, especially when there exists a
large difference in the number of samples of each class.31 In this case, accuracy is heavily
weighted towards the class with the larger number of samples.32 The F1 score is a frequently
used statistic to evaluate the predictive power of a classifier; however, it also ignores the
true negative group. Thus, an additional statistical evaluator was employed, the Matthews
correlation coefficient, which is dependent on the correct prediction of both the positive
and negative classes.30
Feature selection was conducted using a Minimum Redundancy Maximum
Relevancy (mRMR) algorithm. This algorithm seeks to find a set of features from the
sample set that can effectively represent the response and minimize the redundancy of the
feature set through the use of mutual information of the feature variables, or by how much
the uncertainty of a variable in the set can be minimized by information of another variable.
As a result, a higher weighting of a variable due to the algorithm is proportional to its
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confidence, and so is the difference between a variable and the subsequent variable in the
ranking.33
In an effort to improve the predictive capabilities of these models and biomarkers
for the diagnosis of LVH and DHF in patients, it was hypothesized that further exploration
into the biochemical biomarkers could provide more information regarding matrix
turnover. The machine learning approaches mentioned above relay little mechanistic
information, and the combinatory power of black-box machine learning approaches along
with a more comprehensive analysis of the underlying mechanisms affecting hypertrophy
and heart failure could provide improved classification.

Mechanistic Model Approach
A thorough literature review was conducted in order to propose a more
comprehensive mechanistic model of collagen turnover and tissue remodeling. However;
a simple model consisting of the biomarkers noted the previous work was constructed in
order to minimize the number of parameters that would have to be estimated. The network
consisted of the matrix metallopeptidases, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8,
and MMP-9, their tissue inhibitors, TIMP-1, TIMP-2, TIMP-3, TIMP-4, and a universal
activator, plasmin.14 Type I collagen was chosen as the primary focus of the model due to
the available biomarkers, and because previous studies have shown that diseased heart
tissue experiences a relatively higher increase in type I collagen content compared to type
III collagen content.34 This network was then transformed into a system of ordinary
differential equations through reaction kinetics based on the existing interactions. Figure 1
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The full system of equations can be seen in Appendix A.
Due to the lack of physiologically relevant studies regarding kinetic coefficients of
the various reactions involving the proteases and their inhibitors, a genetic algorithm was
utilized in order to approximate the appropriate kinetic values. The chosen genetic
algorithm consisted of 10 generations, each with a population size of 50 sets of parameters.
The initial constraints for the upper and lower bounds of possible kinetic parameters were
set to 0 and 10 (M*hr -1 for bimolecular reaction coefficients; hr -1 for unimolecular reaction
coefficients), respectively, in an effort to avoid constraining the algorithm too tightly.
Through the use of the ODE45 built-in MATLAB solver, the kinetic parameters were
approximated. Within each iteration of the genetic algorithm, the model evaluated the
equations at each time step and the end values for type I collagen of each patient were
ranked in descending order. Following the number of patients diagnosed with DHF, the top
60 ranked patients were noted. The patients could then be classified, and the sensitivities
and specificities of the classification attempts were calculated as followed:
𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =

'*
'* ) +(

; 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =

'(
'( ) +*

.

In an effort to minimize the bias within the mechanistic model towards either
sensitivity or specificity, an additional metric for model validation was calculated as
follows: 1 − (

;39;8!8<8!= ) ;,378>878!=
#

). This metric was utilized as the genetic algorithm’s

fitness function in order to rank each member within a select population. The fitness scores
were then scaled to become expectation values, from which the parent variables could be
selected. The members of the population with the best expectation scores were directly
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passed onto the next generation, and other parent members were altered in order to create
children variables through mutation or crossover.35
For initial conditions, the degraded type I collagen term and mature MMP-1, MMP2, MMP-3, MMP-7, MMP-8, and MMP-9 were all set to zero in order to minimize the
number of unknown variables and parameters. The arrays for the blood plasma panels
utilized in the study by Zile et al. detected differing amounts of each proMMP and mature
MMP, and thus, those markers were assigned completely to the pro-proteases. Therefore,
the initial values for proMMP-1, proMMP-2, proMMP-3, proMMP-7, proMMP-8,
proMMP-9, TIMP-1, TIMP-2, TIMP-3, TIMP-4, and PINP were set to the values derived
from their plasma studies. The initial value for type I collagen was set to the product of the
average of the MMP values and a constant. The initial value for plasmin was set to the
product of the average of the TIMP values and another constant, different than the one for
type I collagen content. The values for type I collagen and plasmin were approximated
because the biomarker array from the previous study did not include exact markers that
could be used as a measurement for an initial boundary in the model. In order to simplify
the building of the model, the co-interactions between active MMPs and other proMMPs
were ignored. Additionally, each TIMP interaction with active MMPs was considered
without any set kinetic boundaries.14
This new variable (type I collagen content at the end of simulation) was then used
within the machine learning framework as a means to provide a mechanistic component to
the classification problems as previously defined. The new variable was imported into the
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set and the same methodology as previously discussed in the “Machine Learning
Algorithms for Classification” section was followed.
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CHAPTER THREE
RESULTS
Initial Classification Attempts
After the selected classification simulations were completed, their accuracies and
areas under their respective receiver operator characteristic (ROC) curves were recorded
(Figure 2). ROC curves display the true positive and false positive rates at various
thresholds for classification. It can be seen that the ROC curves of each model followed a
similar trend when compared to the average ROC curve for LVH classification recorded
by Zile et al. For the expanded profile; however, the curves for certain algorithms seem to
overperform the reported LVH classification. Alternatively, for DHF classification with
the limited panel, it can be seen that many of the models show improved results over the
reported ROC for DHF classification. With the expanded biomarker panel, the ROC curves
of the various models again show improved performance compared to the reported curve;
however, there seems to be minimal improvement over the limited panel.

15

Sensitivity

1 - Specificity

Figure 2: Receive operator characteristic curves for classification of LVH and DHF
(limited), LVH and DHF (expanded), and the best classification models.
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Figure 3 displays the means of the area under the curves of the receiver operator
characteristic curves (3a) and accuracies of classification (3b) of each group, as well as
the results of each individual simulation.

Figure 3a: AUC of ROC curves of various machine learning approaches
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Figure 3b: Accuracies for classification using various machine learning approaches

The results of the feature selection approach are shown in Figure 4. The mostheavily weighted features for the limited LVH classification include: MMP-1, heart rate,
systolic pressure, NT-proBNP, MMP-9, TIMP-1, MMP-2, sex, CITP, and PINP. For the
limited DHF classification, the top selected features are: MMP-1, PIIINP, TIMP-4, heart
rate, NT-proBNP, systolic pressure, MMP-9, TIMP-1, age, and osteopontin. For the
expanded LVH classification, EDS and PSS emerged as significant features. Additionally,
for the expanded DHF classification, ESS appeared to be heavily weighted.
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Figure 4: Feature selection by mRMR for classification problems; green features
represent demographic markers, blue features represent biochemical markers, purple
features represent mechanical markers
Classification Between Disease States
Figure 5 shows the ROC curves for each of the outlines machine learning
approaches when applied to the problem of LVH vs. DHF classification. It can be noted
that the ensemble technique (AdaBoost) provided the highest AUC (0.91) as well as the
highest accuracy (88.3%). For the case of binary classification between LVH and DHF
patients, the top features were MMP-1, EDS, MMP-3, TIMP-4, MMP-2, PINP, NTproBNP, PIIINP, MMP-8, and osteopontin. Notably, all of these top features, other than
end diastolic stress, were biochemical biomarkers, many of which were included in the
simple mechanistic model for type I collagen turnover through protease degradation.
Although not the focus of this study, the classification through biomarkers of these disease
states opens a potential future area of study, and can provide a glimpse into the mechanistic
occurrences that mark the evolution of LVH to DHF.
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Figure 5: ROC curves of the machine learning approaches for LVH vs. DHF
classification
Mechanistic Modeling
After performing the genetic algorithm to solve patient-specific simulations of type
I collagen turnover, the last simulation was used to generate curves for collagen
concentration over time for each patient (Figure 6a). Figure 6b shows a box and whisker
plot with the interquartile ranges for the patient specific simulations split into the
designated patient groups, as well as the values for type I collagen content in every patient
at the model’s endpoint. It can be seen that the means of each patient group do not vary
significantly. However, there exists multiple patients within both the control group and
LVH group that have higher endpoint collagen content than any of the patients within the
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Figure 6b: Type I collagen content of each patient at endpoint of simulation
The inclusion of the collagen term into the machine learning framework was
hypothesized to increase the predictive power of the classification models for patients with
LVH and DHF; however, this is shown to not be true. It can be seen that the inclusion of
the patient-specific collagen content variable does not produce a significant change to the
ROC curves of any of the LVH or DHF classifications (Figures 7a, 7b). Additionally, after
feature selection with the mRMR algorithm, it was found that this new variable scored
poorly in all of the classification scenarios. This variable ranked 24/25 for the limited array
LVH classification, 25/25 for the limited array DHF classification, 28/35 for the expanded
array LVH classification, and 30/35 for the expanded array DHF classification.
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Figure 7a: ROC curves for best LVH classification with and without mechanistic input

Figure 7b: ROC curves for best DHF classification with and without mechanistic input
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The F1 scores and Matthews correlation coefficients for the classification problems
with the limited profile, expanded profile, and expanded profile plus the mechanistic
variable are shown in Table 1. For LVH classification, the highest F1 scores calculated
were for SVM with the expanded profile, and naïve Bayes and logistic regression with the
expanded profile plus mechanistic constant. For DHF classification, the highest F1 scores
calculated were for naïve Bayes and AdaBoost with the expanded profile, and decision tree
with the expanded profile plus mechanistic constant. Additionally, for LVH classification,
the highest MCCs calculated were for SVM with the expanded profile, and k-NN and SVM
with the limited profile. For DHF classification, the highest MCCs calculated were for
AdaBoost with the expanded profile, AdaBoost with the expanded profile with mechanistic
constant, and naïve Bayes with the limited profile. Interestingly, the AdaBoost
classification model often underperformed with these evaluators when compared to
accuracy and the AUC of ROC curves.
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CHAPTER FOUR
DISCUSSION
Patient Classification
The evolution and progression of pressure overload induced LVH and DHF is
complex and utilizes various mechanistic pathways. As a means of dealing with the
difficulty of mapping the interactions that lead to these cardiac pathologies, a variety of
machine learning approaches was used in order to bypass these mechanistic complexities.
By utilizing advanced machine learning techniques, we looked to minimize the need for
more detailed kinetic studies involving human cardiac cells and the specific roles played
by key factors of matrix turnover. After a survey of multiple approaches, an optimized
ensemble method, specifically the AdaBoost method, was shown to have the highest
predictive power based upon accuracy and the AUC of the ROC curves. Other means of
model evaluation, namely F1 scores and MCCs, showed mixed results for patient
classification, and suggests that different models perform better on different sets of classes
within the data.
Although a classification approach leading to perfect predictive capabilities has not
been discovered, we believe that there are significant limitations in the current work that
limit the models’ predictive power. Firstly, the patient data used in this study consisted of
480 patients, many of whom were previously associated with cardiology clinics and
studies. The study selectively ruled out patients with conditions that could potentially alter
their plasma biomarker levels; however, that list of potential conditions is not all
encompassing, and thus, additional factors that are not considered could have an effect on

26

the patients’ biomarker profiles.4 Additionally, as a result of the restrictions put in place
during patient selection, a larger study with more diverse subjects would be needed in order
to further validate the results found herein and expand these classification models onto
additional subjects.
Another limitation of the current study is the limited array of biomarkers that is
specifically tuned towards extracellular remodeling. Although this focus allows for a more
direct investigation into the correlated mechanistic pathways, a more expansive array of
biomarkers could provide the machine learning approaches with valuable features for
classification. For example, a universal activator, plasmin, was used within the model;
however, there exist multiple other activators with higher specificity related to the
proteases and their inhibitors. Additionally, not all known interactions of the species within
the mechanistic model were considered in an effort to minimize unknown parameters. For
example, the MMPs also exhibit co-activation behavior where mature MMPs can function
as an activating species for other proMMPs.14 Lastly, biomarkers considered in the current
study have multiple functions, and thus, a mechanistic model solely focusing on the process
of fibrillar collagen (type I and type III) synthesis and degradation may not sufficiently
explain each of their individual roles in structural tissue change and diminished heart
function.
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Feature Selection
The mRMR algorithm is a filter method of feature selection which statistically
performs selection based on relationships to the outcome variable and was chosen due to
its generalized use with multiple types of machine learning approaches and its documented
use in biological applications, specifically in areas such as gene expression and protein site
interactions.36-38 In other feature selection algorithms, the highest ranked features are often
highly correlated with each other, and thus, the redundancy of the feature set is high and
there is the possibility of little improvement in predictive power from the top feature set.
Additionally, there is the chance that highly correlated features are selected, and thus the
features selected could represent the most dominant feature relationships within the set. In
this particular study, biomarkers strongly related to one another, such as the proteases and
their tissue inhibitors, were used. The mRMR algorithm seeks to alleviate these frequent
concerns of feature selection by ensuring that the features selected are maximally
dissimilar. As an alternative to the filter-based approach of feature selection performed by
the mRMR algorithm, wrapper methods instead could be used in conjunction with the
machine learning techniques discussed and potentially further improve predictive
capabilities.
After feature analysis was conducted with the mRMR algorithm, MMP-1 was
found to be the highest rated feature in all experimental groups for LVH and DHF
classification. Additionally, PIIINP and TIMP-4 were found to be highly rated features
(second and third, respectively) for DHF classification with the limited and expanded
profile. These findings are corroborated within the previous study by Zile et al. of DHF
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classification through multiple logistic regression. In DHF patients compared to the control
group, increased PIIINP is highly indicative of accelerated fibrillar production and
increased TIMP-4 is indicative of collagen breakdown with high cardiovascular
expression. Combined, these biomarkers are shown to be indicative of accelerated levels
of extracellular remodeling that is in accordance with the known effects of fibrotic events
in heart failure.39 Interestingly, NT-proBNP, the current gold-standard biomarker in
hypertrophic disease states, dropped in the feature rankings for the expanded profile of
LVH classification from fourth to fourteenth place.40 Notably, feature selection showed the
emergence of peak systolic and end diastolic stress as important features that are heavily
based upon echocardiographic data relating to the structure of the heart. Due to the mRMR
approach of feature selection, the decrease in ranking of NT-proBNP could signal a strong
correlation between the natriuretic propeptide and heart structure; a relationship that has
been previously established.41
For the expanded profile for DHF classification, end systolic stress arose as a highly
rated feature. There is significant evidence of end systolic stress, or the afterload of heart
contractions, being associated with pathologies related to diminished ventricular function,
such as cardiomyopathy and arterial stenosis.42,43 In all classification problems, MMP-9
and TIMP-1 were ranked in the top ten of features. While there are not direct conclusions
to be made from these results, further specific investigation of the mechanistic roles of
MMP-9 and TIMP-1 in hypertrophic diseases states is warranted.
The results from the feature selection of LVH vs. DHF classification provide
motivation for the inclusion of a mechanistic model to classification of these diagnoses.

29

Since many of the top features from this simulation were biomarkers associated with matrix
turnover, we provide patient-based evidence supporting the explanation that large-scale
tissue remodeling is associated with the evolution from LVH to DHF.

Future
The work herein shows promise of the use of advanced machine learning
techniques for the classification of patients with specific heart pathologies, specifically
those with DHF. A more comprehensive study with a larger patient sampling pool and
additional biomarkers in the panel could provide evidence for the clinical application of
the AdaBoost boosting algorithm for these classification problems.
The complete network modeling all of the underlying mechanisms of collagen
turnover in healthy and diseased heart tissue is unknown. Accordingly, the mechanistic
work done with the intention of its application towards patient classification would benefit
from further research into these interactions, as well as further chemical studies of kinetic
activity of the associated enzymes and their inhibitors. For example, the process of
activation and inhibition in regard to enzymes and substrates does not occur immediately.
Instead, each process entails multiple dynamic steps with their own kinetic behaviors.
These behaviors would be better represented with multiple different equations and would
also introduce new kinetic parameters to the ODE system. For example, the inhibition of
each mature protease by the TIMPs could create a TIMP:MMP complex, each with its own
unique kinetic characteristics. Additionally, the activation steps from proMMPs into active
MMPs could better be represented with equations that recognize their fragmentation as part
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of their maturation processes.14 We believe that further expansion of the kinetic equations
would provide further differentiation between patient curves of type I collagen, and thus,
lead to creating a more useful machine learning feature for classification.
A current concern of this project relates to the process of validation of the
mechanistic model proposed herein. In order to validate that the model can correctly predict
the behavior of the biomarkers, and specifically collagen, over time, various in vitro and in
vivo models can be utilized. Currently, research is being conducted on in vitro experimental
methods to study collagen turnover, specifically in regard to myocardial tissue remodeling.
In these studies, biologically relevant combinations of the proteases and their inhibitors are
added together and observed. As an immediate, simple form of model validation for the
proposed mechanistic model, patient specific cocktails of the elements within the model
can be observed for the trends that are recognized by the defined network model. A more
advanced in vivo method for model validation could be a longitudinal study of collagen
turnover in control and hypertrophic patients over an extended amount of time. Ideally, this
study would take place over a timespan of multiple years in order to track the components
of the biomarker panel over the evolution of tissue remodeling. These clinical steps taken
could provide further insight into the patient-specific details of the development of
hypertrophic pathologies in this patient population through the analysis of collagen
accumulation biomarkers.
Further investigation into the time-dependence of the elements within the model is
also warranted. As an alternative to the simple ODE system proposed, an expanded model
composed of delay partial differential equations could be developed. This evolved model

31

could account for some of the intricacies of protein interactions, and also could help further
understand the body’s time-dependent responses to tissue remodeling. In order to utilize
this more advanced system, additional collections of plasma biomarkers at various
timepoints would be needed.
The creation of a more expansive systems network could also provide interesting
insights into the mechanisms underlying these complex pathologies. Current studies into
possible biomarkers for the classification of heart failure with preserved ejection fraction
show the promise of MR-proANP, MR-proADM, troponins, sST2, GDF-15, and galectin3.44 By using a similar approach as described in this study to a multiscale mechanistic
model, we could potentially recognize other molecules with high kinetic activities that are
associated with hypertrophic heart failure.
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Appendix A
Complete Mechanistic ODE System
𝑑(𝐶. 𝐼)
= F𝑘,-./0.2 ∗ 𝑃𝐼𝑁𝑃I − F𝑘/3455*" ∗ 𝑀𝑀𝑃1 ∗ 𝐶. 𝐼I
𝑑𝑡
− F𝑘/3455*# ∗ 𝑀𝑀𝑃2 ∗ 𝐶. 𝐼I − F𝑘/3455*? ∗ 𝑀𝑀𝑃3 ∗ 𝐶. 𝐼I
− F𝑘/3455*@ ∗ 𝑀𝑀𝑃7 ∗ 𝐶. 𝐼I − F𝑘/3455*A ∗ 𝑀𝑀𝑃8 ∗ 𝐶. 𝐼I
− (𝑘/3455*B ∗ 𝑀𝑀𝑃9 ∗ 𝐶. 𝐼)
𝑑(𝑑𝑒𝑔𝐶. 𝐼)
= (𝑘/3455*" ∗ 𝑀𝑀𝑃1 ∗ 𝐶. 𝐼) + (𝑘/3455*# ∗ 𝑀𝑀𝑃2 ∗ 𝐶. 𝐼)
𝑑𝑡
+ (𝑘/3455*? ∗ 𝑀𝑀𝑃3 ∗ 𝐶. 𝐼) + (𝑘/3455*@ ∗ 𝑀𝑀𝑃7 ∗ 𝐶. 𝐼)
+ (𝑘/3455*A ∗ 𝑀𝑀𝑃8 ∗ 𝐶. 𝐼) + (𝑘/3455*B ∗ 𝑀𝑀𝑃9 ∗ 𝐶. 𝐼)
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃1)
= −(𝑘67!55*" ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃1)
𝑑𝑡
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃2)
= −(𝑘67!55*# ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃2)
𝑑𝑡
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃3)
= −(𝑘67!55*? ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃3)
𝑑𝑡
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃7)
= −(𝑘67!55*@ ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃7)
𝑑𝑡
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃8)
= −(𝑘67!55*A ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃8)
𝑑𝑡
𝑑(𝑝𝑟𝑜𝑀𝑀𝑃9)
= −(𝑘67!55*B ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃9)
𝑑𝑡
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𝑑(𝑀𝑀𝑃1)
= (𝑘67!55*" ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃1) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃4)
𝑑(𝑀𝑀𝑃2)
= (𝑘67!55*# ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃2) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃4)
𝑑(𝑀𝑀𝑃3)
= (𝑘67!55*? ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃3) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃4)

𝑑(𝑀𝑀𝑃7)
= (𝑘67!55*@ ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃7) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃4)

𝑑(𝑀𝑀𝑃8)
= (𝑘67!55*A ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃8) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃4)
𝑑(𝑀𝑀𝑃9)
= (𝑘67!55*B ∗ 𝑝𝑙𝑎𝑠𝑚𝑖𝑛 ∗ 𝑝𝑟𝑜𝑀𝑀𝑃9) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃1)
𝑑𝑡
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃4)
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/('25*")

= − (𝑘89:'25*" ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃1) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃1) −
(𝑘89:'25*" ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃1) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃1)
− (𝑘89:'25*" ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃1) − (𝑘89:'25*" ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃1)
/!

/('25*#)

= − (𝑘89:'25*# ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*# ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃2) −
(𝑘89:'25*# ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*# ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃2)
− (𝑘89:'25*# ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃2) − (𝑘89:'25*# ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃2)
/!

/('25*?)

= − (𝑘89:'25*? ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃3) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃3) −
(𝑘89:'25*? ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃3) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃3)
− (𝑘89:'25*? ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃3) − (𝑘89:'25*? ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃3)
/!

/('25*C)

= − (𝑘89:'25*C ∗ 𝑀𝑀𝑃1 ∗ 𝑇𝐼𝑀𝑃4) − (𝑘89:'25*C ∗ 𝑀𝑀𝑃2 ∗ 𝑇𝐼𝑀𝑃4) −
(𝑘89:'25*C ∗ 𝑀𝑀𝑃3 ∗ 𝑇𝐼𝑀𝑃4) − (𝑘89:'25*C ∗ 𝑀𝑀𝑃7 ∗ 𝑇𝐼𝑀𝑃4)
− (𝑘89:'25*C ∗ 𝑀𝑀𝑃8 ∗ 𝑇𝐼𝑀𝑃4) − (𝑘89:'25*C ∗ 𝑀𝑀𝑃9 ∗ 𝑇𝐼𝑀𝑃4)
/!
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